Showing 621 - 640 results of 1,160 for search '(( significant decrease decrease ) OR ( significant adverse decrease ))~', query time: 0.35s Refine Results
  1. 621

    Image 1_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
  2. 622

    Image 2_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
  3. 623

    Image 5_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
  4. 624

    Data Sheet 2_Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes... by Yao Wang (102387)

    Published 2025
    “…Older patients receiving SGLT2i had a greater incidence of euglycemic ketoacidosis (EKA) (OR 1.622, 95% CI 1.276-2.062, p = 0.000) and genitourinary infection (GUI) (OR 3.59, 95% CI 3.31-3.89, p = 0.00) than did those receiving GLP-1RA, and the opposite was true for acute kidney injury (AKI) (OR 0.902, 95% CI 0.854 - 0.952, p = 0.00). However, no significant differences were detected for major adverse cardiovascular events (MACE) (OR 1.04, 95% CI 0.95-1.13, p = 0.386), hospitalization for heart failure (HHF) (OR 0.98 95% CI 0.83-1.16, p = 0.825), myocardial infarction (MI) (OR 1.09, 95% CI 0.94-1.26, p = 0.265), stroke (OR 1.22, 95% CI 1.02-1.45, p = 0.028), total adverse events (AEs), (OR 0.98, 95% CI 0.83-1.16, p = 0.825), serious AEs (OR 1.02, 95% CI 0.94 -1.11, p = 0.594), fractures (OR 1.07, 95% CI 0.92-1.24, p = 0.394) or hypoglycemia (OR 0.95, 95% CI 0.88-1.02, p = 0.141).…”
  5. 625

    Data Sheet 1_Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes... by Yao Wang (102387)

    Published 2025
    “…Older patients receiving SGLT2i had a greater incidence of euglycemic ketoacidosis (EKA) (OR 1.622, 95% CI 1.276-2.062, p = 0.000) and genitourinary infection (GUI) (OR 3.59, 95% CI 3.31-3.89, p = 0.00) than did those receiving GLP-1RA, and the opposite was true for acute kidney injury (AKI) (OR 0.902, 95% CI 0.854 - 0.952, p = 0.00). However, no significant differences were detected for major adverse cardiovascular events (MACE) (OR 1.04, 95% CI 0.95-1.13, p = 0.386), hospitalization for heart failure (HHF) (OR 0.98 95% CI 0.83-1.16, p = 0.825), myocardial infarction (MI) (OR 1.09, 95% CI 0.94-1.26, p = 0.265), stroke (OR 1.22, 95% CI 1.02-1.45, p = 0.028), total adverse events (AEs), (OR 0.98, 95% CI 0.83-1.16, p = 0.825), serious AEs (OR 1.02, 95% CI 0.94 -1.11, p = 0.594), fractures (OR 1.07, 95% CI 0.92-1.24, p = 0.394) or hypoglycemia (OR 0.95, 95% CI 0.88-1.02, p = 0.141).…”
  6. 626

    Data Sheet 1_Efficacy and safety of reduning injection for severe pneumonia: a systematic review and meta-analysis.docx by Yan Wang (15435)

    Published 2025
    “…Lastly, not all studies reported any serious adverse events; however, some studies did report adverse reactions.…”
  7. 627

    Table 1_Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mell... by Yao Wang (102387)

    Published 2025
    “…Older patients receiving SGLT2i had a greater incidence of euglycemic ketoacidosis (EKA) (OR 1.622, 95% CI 1.276-2.062, p = 0.000) and genitourinary infection (GUI) (OR 3.59, 95% CI 3.31-3.89, p = 0.00) than did those receiving GLP-1RA, and the opposite was true for acute kidney injury (AKI) (OR 0.902, 95% CI 0.854 - 0.952, p = 0.00). However, no significant differences were detected for major adverse cardiovascular events (MACE) (OR 1.04, 95% CI 0.95-1.13, p = 0.386), hospitalization for heart failure (HHF) (OR 0.98 95% CI 0.83-1.16, p = 0.825), myocardial infarction (MI) (OR 1.09, 95% CI 0.94-1.26, p = 0.265), stroke (OR 1.22, 95% CI 1.02-1.45, p = 0.028), total adverse events (AEs), (OR 0.98, 95% CI 0.83-1.16, p = 0.825), serious AEs (OR 1.02, 95% CI 0.94 -1.11, p = 0.594), fractures (OR 1.07, 95% CI 0.92-1.24, p = 0.394) or hypoglycemia (OR 0.95, 95% CI 0.88-1.02, p = 0.141).…”
  8. 628

    Supplemental information to: Female mice with HSD17B1 inactivation show mild hyperandrogenism without notable impact on reproductive function or bone by Arttu Junnila (22503041)

    Published 2025
    “…Our results demonstrate that the blockade of HSD17B1-dependent E2 synthesis is successfully compensated for in mouse<i> in vivo</i>, resulting in only a mild ovarian estrogen and androgen imbalance, but no significant adverse effects on reproductive or bone health.…”
  9. 629

    Video 2_Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe feline chronic kidney disease.mp4 by Yizhe Song (11859734)

    Published 2025
    “…Concurrently, laboratory results revealed a decrease in key renal biomarkers (SCr, BUN, and P) and an amelioration of the non-regenerative anemia. …”
  10. 630

    Data Sheet 1_Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial.pdf by Li-qin Meng (20633030)

    Published 2025
    “…After treatment, three-months major adverse cardiovascular events (MACE) were assessed as the primary outcome. …”
  11. 631

    Video1_One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy.mov by Daniel Seung Kim (19510291)

    Published 2024
    “…Adverse events were rare, unrelated to mavacamten itself, and seen solely in patients with disease too advanced to have been represented in clinical trials. …”
  12. 632

    Video 1_Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe feline chronic kidney disease.mp4 by Yizhe Song (11859734)

    Published 2025
    “…Concurrently, laboratory results revealed a decrease in key renal biomarkers (SCr, BUN, and P) and an amelioration of the non-regenerative anemia. …”
  13. 633

    Video 3_Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe feline chronic kidney disease.mp4 by Yizhe Song (11859734)

    Published 2025
    “…Concurrently, laboratory results revealed a decrease in key renal biomarkers (SCr, BUN, and P) and an amelioration of the non-regenerative anemia. …”
  14. 634

    Table 1_Hesperidin alleviates hypothyroidism-related cardiac dysfunction by targeting cardiac miRNAs, Nrf2/NF-κB signaling, oxidative stress and inflammation.docx by Asmaa M. Gaber (21640814)

    Published 2025
    “…</p>Results<p>CMZ intake resulted in a significant decrease in thyroid hormones (THs) levels with a subsequent increase in serum thyroid stimulating hormone and cardiac enzymes activities, dyslipidemia, and body weight gain. …”
  15. 635

    Data Sheet 1_Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe feline chronic kidney disease.pdf by Yizhe Song (11859734)

    Published 2025
    “…Concurrently, laboratory results revealed a decrease in key renal biomarkers (SCr, BUN, and P) and an amelioration of the non-regenerative anemia. …”
  16. 636

    Video 4_Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe feline chronic kidney disease.mp4 by Yizhe Song (11859734)

    Published 2025
    “…Concurrently, laboratory results revealed a decrease in key renal biomarkers (SCr, BUN, and P) and an amelioration of the non-regenerative anemia. …”
  17. 637

    Data Sheet 1_Effects of continuous cropping on soil metabolomics and rhizosphere bacterial communities in Panax quinquefolius L..docx by Jian Song (4232)

    Published 2025
    “…Microbial community composition was assessed using Illumina high-throughput sequencing, and metabolite profiles were analyzed using non-targeted metabolomics (UPLC-MS/MS).</p>Results<p>Significant decreases were observed in soil pH (12.2–28.0%), cation exchange capacity (42.6–65.5%), organic matter (8.7–27.3%), total nitrogen (7.6–27.8%), and ammonium (NH<sub>4</sub><sup>+</sup>) content (16.9–56.6%) with an increasing number of continuous cropping years. …”
  18. 638

    Table 5_Active ingredients isolated from Periplaneta americana L. inhibit the inflammation of the colonic mucosa and regulate the gut microbiota in DSS-induced ulcerative colitis i... by Yanhuan Wang (12037016)

    Published 2025
    “…Current therapies often have significant limitations, including adverse effects, highlighting the need for safer alternatives. …”
  19. 639

    Data Sheet 2_Effects of continuous cropping on soil metabolomics and rhizosphere bacterial communities in Panax quinquefolius L..docx by Jian Song (4232)

    Published 2025
    “…Microbial community composition was assessed using Illumina high-throughput sequencing, and metabolite profiles were analyzed using non-targeted metabolomics (UPLC-MS/MS).</p>Results<p>Significant decreases were observed in soil pH (12.2–28.0%), cation exchange capacity (42.6–65.5%), organic matter (8.7–27.3%), total nitrogen (7.6–27.8%), and ammonium (NH<sub>4</sub><sup>+</sup>) content (16.9–56.6%) with an increasing number of continuous cropping years. …”
  20. 640

    Table 2_Active ingredients isolated from Periplaneta americana L. inhibit the inflammation of the colonic mucosa and regulate the gut microbiota in DSS-induced ulcerative colitis i... by Yanhuan Wang (12037016)

    Published 2025
    “…Current therapies often have significant limitations, including adverse effects, highlighting the need for safer alternatives. …”